CI · Cigna Group - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $274.90B | $247.12B | $195.26B | $180.52B | $174.08B | $160.40B |
| Cost of Revenue | $214.99B | $182.51B | $133.80B | $124.83B | $117.55B | $103.48B |
| Gross Profit | $59.91B | $64.61B | $61.46B | $55.68B | $56.52B | $56.92B |
| R&D | - | - | - | - | - | - |
| SG&A | $14.62B | $14.84B | $14.82B | $13.19B | $13.03B | $14.07B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $2.77B | $2.77B | $3.04B | $2.94B | $2.92B | $2.80B |
| Operating Income | $9.20B | $9.42B | $8.54B | $8.41B | $7.93B | $8.15B |
| Interest Expense | $1.40B | $1.50B | $1.40B | $1.30B | $1.30B | $1.40B |
| Income Tax | $1.49B | $1.49B | $141.00M | $1.61B | $1.37B | $2.38B |
| Net Income | $3.43B | $3.43B | $5.16B | $6.67B | $5.37B | $8.46B |
| EPS - Basic | $22.33 | $12.25 | $17.57 | $21.54 | $15.87 | $23.17 |
| EPS - Diluted | $22.18 | $12.12 | $17.39 | $21.30 | $15.73 | $22.96 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.68B | $7.55B | $7.82B | $5.92B | $5.08B | $10.18B |
| Accounts Receivable | $28.77B | $24.23B | $17.72B | $17.22B | $15.07B | $12.19B |
| Inventory | $7.34B | $6.69B | $5.64B | $4.78B | $3.72B | $3.17B |
| Accounts Payable | $10.66B | $9.29B | $8.55B | $7.78B | $6.66B | $5.48B |
| Current Assets | $47.81B | $48.87B | $37.35B | $30.12B | $36.13B | $27.80B |
| Total Assets | $157.92B | $155.88B | $152.76B | $143.93B | $154.89B | $155.45B |
| Current Liabilities | $56.34B | $57.98B | $48.72B | $41.23B | $43.57B | $36.02B |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $116.05B | $114.64B | $106.41B | $98.98B | $107.70B | $105.06B |
| Stockholders' Equity | $41.71B | $41.03B | $46.22B | $44.87B | $47.11B | $50.32B |
| Retained Earnings | $47.87B | $43.52B | $41.65B | $37.87B | $32.59B | $28.57B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.60B | $10.36B | $11.81B | $8.66B | $7.19B | $10.35B |
| Investing Cash Flow | ($4.41B) | ($2.10B) | ($5.17B) | $3.10B | ($3.61B) | $2.98B |
| Financing Cash Flow | ($6.42B) | ($7.65B) | ($4.29B) | ($11.24B) | ($8.21B) | ($8.53B) |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 21.8% | 26.1% | 31.5% | 30.8% | 32.5% | 35.5% |
| Operating margin | 3.3% | 3.8% | 4.4% | 4.7% | 4.6% | 5.1% |
| EBITDA margin | 4.4% | 4.9% | 5.9% | 6.3% | 6.2% | 6.8% |
| Net margin | 1.2% | 1.4% | 2.6% | 3.7% | 3.1% | 5.3% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 5.3% | 6.0% | 7.6% | 7.3% | 7.5% | 8.8% |
| Effective tax rate | 30.3% | 30.3% | 2.7% | 19.4% | 20.3% | 22.0% |
| Return on assets | 2.2% | 2.2% | 3.4% | 4.6% | 3.5% | 5.4% |
| Return on equity | 8.2% | 8.4% | 11.2% | 14.9% | 11.4% | 16.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.85 | 0.84 | 0.77 | 0.73 | 0.83 | 0.77 |
| Quick ratio | 0.72 | 0.73 | 0.65 | 0.61 | 0.74 | 0.68 |
| Cash ratio | 0.14 | 0.13 | 0.16 | 0.14 | 0.12 | 0.28 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 6.6x | 6.3x | 6.1x | 6.5x | 6.1x | 5.8x |
| Equity multiplier | 3.79 | 3.80 | 3.30 | 3.21 | 3.29 | 3.09 |
| Liabilities / Assets | 0.73 | 0.74 | 0.70 | 0.69 | 0.70 | 0.68 |
| Efficiency | ||||||
| Asset turnover | 1.74 | 1.59 | 1.28 | 1.25 | 1.12 | 1.03 |
| Inventory turnover | 29.30 | 27.27 | 23.70 | 26.13 | 31.58 | 32.70 |
| Days sales outstanding | 38d | 36d | 33d | 35d | 32d | 28d |
| Days inventory outstanding | 12d | 13d | 15d | 14d | 12d | 11d |
| Days payable outstanding | 18d | 19d | 23d | 23d | 21d | 19d |
| Cash conversion cycle | 33d | 31d | 25d | 26d | 22d | 20d |
| Valuation | ||||||
| P / E | 12.4x | 22.8x | 17.2x | 15.6x | 14.6x | 9.1x |
| P / B | 1.8x | 1.9x | 1.9x | 2.3x | 1.7x | 1.5x |
| P / S | 0.3x | 0.3x | 0.5x | 0.6x | 0.4x | 0.5x |
| EV / EBITDA | 5.5x | 5.8x | 7.0x | 8.6x | 6.7x | 6.1x |
| Growth | ||||||
| Revenue growth (YoY) | 11.2% | 26.6% | 8.2% | 3.7% | 8.5% | 4.5% |
| Revenue CAGR (3y) | 15.0% | 12.4% | 6.8% | 5.5% | 63.5% | - |
| Revenue CAGR (5y) | 11.4% | 10.0% | 37.4% | - | - | - |
| Gross profit growth (YoY) | -7.3% | 5.1% | 10.4% | -1.5% | -0.7% | 1.8% |
| Operating income growth (YoY) | -2.3% | 10.3% | 1.4% | 6.0% | -2.7% | 0.9% |
| Net income growth (YoY) | 0.0% | -33.5% | -22.6% | 24.3% | -36.6% | 65.7% |
| EPS growth (YoY) | 83.0% | -30.3% | -18.4% | 35.4% | -31.5% | 70.8% |
| EPS CAGR (3y) | 1.4% | -8.3% | -8.8% | 16.6% | 29.8% | - |
| EPS CAGR (5y) | -0.7% | -2.0% | 19.3% | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 1.7% | -11.2% | 3.0% | -4.8% | -6.4% | 11.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$283.04B totalEvernorth$234.95B · 83.0%
Cigna Healthcare$47.41B · 16.8%
All Other Segments$674.00M · 0.2%
Product / service
$469.10B totalProduct$216.67B · 46.2%
Network Pharmacy$125.57B · 26.8%
Home Delivery And Specialty$80.49B · 17.2%
Service$16.92B · 3.6%
Service Fees And Other Revenues$15.42B · 3.3%
Other Pharmacy$13.33B · 2.8%
Service Other$696.00M · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.29
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Hospital & Medical Service Plans
Comparing Cigna Group against the 5 most active filers in the same SIC group.
Dividends
$4.58/share trailing 12 months · -21.3% YoY
| Ex-date | Per share |
|---|---|
| Mar 5, 2026 | $1.5600 |
| Dec 4, 2025 | $1.5100 |
| Sep 4, 2025 | $1.5100 |
| Jun 3, 2025 | $1.5100 |
| Mar 5, 2025 | $1.5100 |
| Dec 4, 2024 | $1.4000 |
| Sep 4, 2024 | $1.4000 |
| Jun 4, 2024 | $1.4000 |
| Mar 5, 2024 | $1.4000 |
| Dec 5, 2023 | $1.2300 |
| Sep 5, 2023 | $1.2300 |
| Jun 6, 2023 | $1.2300 |
| Mar 7, 2023 | $1.2300 |
| Dec 5, 2022 | $1.1200 |
| Sep 6, 2022 | $1.1200 |
| Jun 7, 2022 | $1.1200 |
| Mar 8, 2022 | $1.1200 |
| Dec 6, 2021 | $1.0000 |
| Sep 7, 2021 | $1.0000 |
| Jun 7, 2021 | $1.0000 |
| Mar 9, 2021 | $1.0000 |
| Mar 9, 2020 | $0.0400 |
| Mar 8, 2019 | $0.0400 |
| Mar 9, 2018 | $0.0400 |